🧴 RETATRUTIDE – 60 MG KIT (12 MG / VIAL × 5 VIALS) – ZPHC PHARMA
🧪 Product Type
Peptide / Multi-Agonist Hormonal Therapy
Active Ingredient: Retatrutide
Dosage Form: Lyophilized powder for reconstitution
Total Kit Strength: 60 MG
Vial Strength: 12 MG per vial
Package Content: 5 vials per kit
📄 Description
RETATRUTIDE by ZPHC Pharma is a next-generation multi-agonist peptide that targets GLP-1, GIP, and glucagon receptors, making it a highly promising candidate for advanced weight management, metabolic optimization, and type 2 diabetes support.
This formulation is designed for research purposes only, providing insight into how triple agonists can influence appetite regulation, insulin sensitivity, and fat oxidation.
🔹 Product Features
- Concentration: 12 MG of Retatrutide per vial
- Total Dose: 60 MG per kit (5 vials × 12 MG)
- Form: Lyophilized powder – requires reconstitution with bacteriostatic water
- Storage: Store refrigerated (2°C–8°C) after reconstitution
- Purity: Pharmaceutical-grade research peptide
✅ Key Research Benefits
- 🔥 Appetite Suppression: Enhances satiety and reduces caloric intake
- 💪 Fat Loss & Metabolic Boost: Supports thermogenesis and fat breakdown
- 💉 Insulin Sensitivity: Improves glucose uptake and beta-cell function
- 🧪 Triple Receptor Action: Acts simultaneously on GLP-1, GIP & glucagon receptors for comprehensive metabolic modulation
📈 Suggested Research Use (For Investigational Use Only)
Retatrutide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water before subcutaneous administration.
Dosage, frequency, and duration should be defined according to the parameters of the research protocol.
⚠️ Potential Side Effects (Observed in Research Contexts)
- Nausea or gastrointestinal discomfort
- Reduced appetite
- Mild injection site reactions
- Potential alterations in glucose metabolism
Monitoring is advised during extended study periods.
🚫 Contraindications (Research Advisory)
Not recommended for use in subjects with:
- History of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known allergy to peptide-based therapeutics
🛒 Purchase Information
- For Research Purposes Only – Not for Human Consumption
- Supplied as: 60 MG KIT (5 vials × 12 MG)
- Manufacturer: ZPHC PHARMA
- Ensure authenticity and quality by ordering through certified research suppliers
- Shipping Time: Typically 5–12 business days based on location
| Brands | ZPHC PHARMA |